UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000017247
Receipt number R000020011
Scientific Title An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without Bevacizumab in Platinum-resistant ovarian cancer patients previously treated with Bevacizumab for front-line or Platinum-sensitive ovarian cancer: -JGOG3023 trial-
Date of disclosure of the study information 2015/04/22
Last modified on 2021/12/13 14:35:58

No. Disposal Last modified on Item of update
1 Insert 2015/04/22 18:56:56
2 Update 2015/05/13 17:43:35 Key exclusion criteria
3 Update 2015/05/13 17:44:55 Key exclusion criteria
4 Update 2015/06/12 17:40:42 Key exclusion criteria
5 Update 2015/06/12 17:42:30 Recruitment status
6 Update 2016/02/25 16:23:28 Last name of lead principal investigator
Last name of lead principal investigator
Organization
Organization
Division name
Division name
Address
Address
TEL
Last name of contact person
Last name of contact person
Organization
Organization
Division name
Division name
Address
Address
TEL
Institutions
7 Update 2016/02/25 16:26:00 Developmental phase
8 Update 2016/02/25 16:37:33 Last name of lead principal investigator
9 Update 2016/02/25 16:40:39 URL releasing protocol
10 Update 2016/06/07 16:09:59 Key exclusion criteria
Key exclusion criteria
11 Update 2016/06/07 17:42:26 Name of primary person or sponsor
Organization
Organization1
Address1
Tel1
Email1
Institutions
12 Update 2016/06/07 18:15:54 Organization
Division name
Address
TEL
Organization
Division name
Address
TEL
13 Update 2016/06/07 18:56:37 Organization
Division name
Address
TEL
Organization
Division name
Address
Institute
14 Update 2016/06/13 16:08:20 Address
Address
Address
15 Update 2017/05/26 16:49:49 Institutions
16 Update 2017/05/26 16:53:24 Last follow-up date
17 Update 2017/10/27 14:39:36 Institutions
18 Update 2018/04/24 15:08:18 Institutions
19 Update 2019/03/22 13:49:14 Condition
Condition
20 Update 2019/03/22 14:12:49 Key inclusion criteria
21 Update 2019/03/22 14:31:09 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Organization
Organization
Division name
Division name
Zip code
Address
Address
TEL
Email

Last name of contact person

Last name of contact person
Organization
Organization
Division name
Division name
Zip code
Address
Address
TEL
Email
Division name
Division name
Organization1
Address1
Tel1
Email1
Organization
Organization
Address
Address
Tel
Email
22 Update 2019/03/22 15:28:25 Institutions
23 Update 2019/03/22 16:23:05 Institutions
24 Update 2019/03/22 16:25:58 Recruitment status
Date of IRB
25 Update 2019/10/30 14:17:23 Zip code
Address
Address
TEL
Zip code
Address
Address
TEL
26 Update 2019/10/30 14:27:26 Date of closure to data entry
Date trial data considered complete
Date analysis concluded
27 Update 2020/07/03 09:53:20 Name of person sending information
Name of person sending information
Organization
Organization
Email
Secondary IDs
Study ID_1
Org. issuing International ID_1
Org. issuing International ID_1
Institutions
28 Update 2020/07/03 09:59:15 Last follow-up date
Date of closure to data entry
29 Update 2021/12/13 14:27:54 Recruitment status
30 Update 2021/12/13 14:33:52 Publication of results
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
31 Update 2021/12/13 14:35:58 Plan to share IPD
Plan to share IPD
IPD sharing Plan description
IPD sharing Plan description